ADC Therapeutics reported fourth‑quarter 2025 results that included net product revenue of $22.3 million, up from $16.4 million in the same quarter of 2024, and a net loss of $6.4 million compared with a $30.7 million loss in Q4 2024. The company posted earnings per share of $‑0.04, a $0.28 improvement over the consensus estimate of $‑0.32, while full‑year 2025 net product revenue reached $73.6 million, up from $69.3 million in 2024, and the full‑year net loss narrowed to $142.6 million from $157.8 million the prior year.
Cash and cash equivalents stood at $261.3 million as of December 31 2025, giving the company a runway that management expects to extend at least through 2028. The strong liquidity position, combined with the absence of debt, provides a cushion for ongoing clinical development and potential regulatory submissions.
ADC also updated the status of its key clinical programs. Topline data from the LOTIS‑5 Phase 3 trial, which combines ZYNLONTA with rituximab in second‑line diffuse large B‑cell lymphoma, is slated for release in the second quarter of 2026, with full results expected by year‑end 2026. The LOTIS‑7 trial, evaluating ZYNLONTA with the bispecific glofitamab, will deliver full data by the end of 2026. In addition, the company completed IND‑enabling activities for its PSMA‑targeting ADC, positioning it for potential regulatory submissions and inclusion in compendia in 2027.
CEO Ameet Mallik said, "Building off the meaningful progress achieved across our ZYNLONTA clinical program in DLBCL and through investigator‑initiated trials in indolent lymphomas this past year, we believe we have laid the foundation for multiple anticipated value‑creating catalysts." CFO Jose Carmona added, "Q4 2025 net product revenues were $22.3 million as compared to $16.4 million in the same quarter in 2024. On a full year basis, net product revenues were $73.6 million versus $69.3 million in 2024, with underlying volume broadly flat."
The earnings beat can be attributed to disciplined cost management and pricing power that offset the modest decline in volume. Revenue growth was driven by higher pricing across the product portfolio, while the company maintained a stable volume mix, mitigating the impact of any seasonal fluctuations. The narrowing of the net loss reflects both the revenue lift and the effectiveness of cost controls, positioning ADC to invest in its pipeline without compromising financial stability.
With a robust cash position, a clear path to regulatory milestones, and a pipeline that is expected to generate significant revenue starting in 2027, ADC Therapeutics is poised to accelerate growth. The company’s focus on expanding the indications for ZYNLONTA and advancing its PSMA‑targeting ADC underscores a strategy aimed at capturing new market share in oncology therapeutics.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.